From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: 4-AcO-DET
Chemical Nomenclature
Common names 4-AcO-DET, 4-Acetoxy-DET, Ethacetin
Substitutive name 4-Acetoxy-N,N-diethyltryptamine
Systematic name 3-(2-(Diethylamino)ethyl)-1H-indol-4-yl acetate
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 5 mg
Light 10 - 15 mg
Common 15 - 20 mg
Strong 20 - 35 mg
Heavy 35 mg +
Total 4 - 7 hours
Onset 20 - 60 minutes
Come up 1 - 1.5 hours
Peak 1.5 - 3 hours
Offset 1 - 2 hours
After effects 2 - 4 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


4-AcO-DET (4-Acetoxy-N,N-diethyltryptamine, ethacetin) is a lesser-known novel psychedelic substance of the tryptamine class. It is chemically related to psilocin and part of a series of substituted tryptamines that includes 4-AcO-MET and 4-AcO-DMT.

Today it is either used recreationally as a designer drug or as an entheogenic compound and is typically acquired through the use of online research chemical vendors.

There is very little data on the human pharmacology or toxicity of 4-AcO-DET, although analytical methods have been developed for its detection.[1] It remains relatively rare and has very little documented history of human usage. It is highly advised to use harm reduction practices if using this substance.


4-AcO-DET, or 4-Acetoxy-N.N-diethyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 4-AcO-DET is substituted at R4 of its indole heterocycle with an acetoxy (AcO) functional group CH3COO−. It also contains two ethyl chains bound to the terminal amine RN of its tryptamine backbone (DET).

4-AcO-DET is the N-substituted diethyl homolog of 4-HO-DMT (psilocin). 4-AcO-DET is the acetate ester analog of DET and the N-substituted diethyl analog of 4-AcO-DMT.[2] It is a higher homolog of 4-AcO-DMT and 4-AcO-MET.


Further information: Serotonergic psychedelic

4-substituted acetylated tryptamines such as 4-AcO-DET, 4-AcO-MET, and 4-AcO-DMT are hypothesized to principally act as a prodrug for their respective hydrolyzed counterparts (e.g. 4-HO-DMT, 4-HO-MET and 4-HO-DET). In theory, they would become inactive until they are deacetylated in the body, although there is on-going discussion as to whether they might display their own intrinsic activity.[citation needed]

Like with most psychedelic tryptamines, 4-AcO-DET is thought to act principally as a 5-HT2A partial agonist. The psychedelic effects are believed to come from 4-AcO-DET's binding efficacy at the 5-HT2A receptors.

However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 4-AcO-DET has not been studied in any scientific context and the exact toxic dose is unknown. This is because 4-AcO-DET is a research chemical with a very limited history of human usage. However, it is assumed to have a similar toxicity profile as psilocybin due to their structural similarity.

Anecdotal reports from those who have tried 4-AcO-DET suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

Although no formal studies have been conducted, it is believed that 4-AcO-DET is not habit-forming and the desire to use it can actually decrease with use.

Tolerance to the effects of 4-AcO-DET is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 4-AcO-DET presents cross-tolerance with all psychedelics, meaning that after the consumption of 4-AcO-DET all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Due to its relative obscurity, the possession and sale of 4-AcO-DET is unscheduled in most countries.

  • Germany: Because it is an ester of DET, 4-AcO-DET is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[4] as of January 24, 1974.[5] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[6]
  • Japan: 4-AcO-DET is a controlled substance in Japan effective July 29th, 2015.[7]
  • Switzerland: 4-AcO-DET is a controlled substance specifically named under Verzeichnis E.[8]
  • Sweden: 4-AcO-DET was classified under the Act on the Prohibition of Certain Goods Dangerous to Health on November 1, 2005, making it illegal to sell or possess.[9]
  • Turkey: 4-AcO-DET is a classed as drug and is illegal to possess, produce, supply, or import.[10][11]
  • United Kingdom: 4-AcO-DET is a Class A drug in the UK as it is an ester of the drug 4-HO-DET, which is a Class A drug as a result of the tryptamine catch-all clause.[12]
  • United States: 4-AcO-DET is unscheduled in the United States. It may be considered an analogue of psilocin (4-HO-DMT) which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.[citation needed]

See also

External links



  1. Takahashi, M.; Nagashima, M.; Suzuki, J.; Yasuda, I; Yoshida, T. (February 15, 2009). "Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry". 77 (4): 1245–1272. doi:10.1016/j.talanta.2008.07.062. eISSN 1873-3573. ISSN 0039-9140. OCLC 01767116. PMID 19084633. 
  2. "Compound Summary - 3-(2-(Diethylamino)ethyl)-1H-indol-4-yl acetate". PubChem. Retrieved July 18, 2020. 
  3. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  4. "Betäubungsmittelgesetz (BtMG) Anlage I" [Narcotics Act (BtMG) Schedule I] (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  5. "Sechste Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe" (PDF). Bundesgesetzblatt Jahrgang 1974 Teil I Nr. 6 (in German). Bundesanzeiger Verlag [Federal Gazette] (published January 23, 1974). January 17, 1974. p. 97. eISSN 0344-7634. 
  6. "Betäubungsmittelgesetz (BtMG) § 29" [Narcotics Act (BtMG) § 29] (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  7. 危険ドラッグの成分4物質を新たに指定薬物に指定 (in Japanese), 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)], retrieved 2 May 2022 
  8. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  9. "Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor" (PDF). Svensk författningssamling (in Swedish). Läkemedelsverket [Medical Products Agency] (published October 18, 2005). October 6, 2005. ISSN 1101-5225. SFS 2005:733. 
  10. "Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742" (in Turkish). Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication] (published January 25, 2014). December 16, 2013. 
  11. "Kararnamenin Eki: Liste" (PDF). Resmî Gazete, Sayı: 28893 (in Turkish). Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication] (published January 25, 2014). December 16, 2013. 2013/5742. 
  12. "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.